immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system.  we are developing molecular and product platforms including n-8

ImmunityBio, Inc. Common Stock

Sold all IBRX

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Riley Wong

Sold 50% of IBRX

Bought 100% more IBRX

New position in IBRX

Andrew emple

Kanoa

Kanoa Cook

Bought 33% more IBRX

Baljinder